With limited cash and a pipeline narrowed to a single drug - Silenor (doxepin), an H1 histamine blocker for insomnia - San Diego-based Somaxon Pharmaceuticals Inc. is crossing its fingers that a reanalysis of clinical data will provide sufficient answers to the FDA's February complete response and finally get the drug to market. (BioWorld Today) Read More